PMID- 37643678
OWN - NLM
STAT- MEDLINE
DCOM- 20231205
LR  - 20240326
IS  - 1534-4436 (Electronic)
IS  - 1081-1206 (Print)
IS  - 1081-1206 (Linking)
VI  - 131
IP  - 6
DP  - 2023 Dec
TI  - Perception of burden of oral and inhaled corticosteroid adverse effects on 
      asthma-specific quality of life.
PG  - 745-751.e11
LID - S1081-1206(23)00636-1 [pii]
LID - 10.1016/j.anai.2023.08.595 [doi]
AB  - BACKGROUND: A multistakeholder core outcome set created for asthma trials showed 
      that asthma-specific quality of life (QoL) was a critically meaningful outcome. 
      However, the definition and measurement methods were undetermined. The adverse 
      effects (AEs) of corticosteroids may be a vital clinical trial outcome. 
      Nevertheless, the AE burden from the patient perspective has not yet been 
      elucidated in an asthma population. OBJECTIVE: To characterize patient burden of 
      AEs in oral (OCS) and inhaled corticosteroids (ICS) and how this relates to QoL 
      within an asthma population. METHODS: We used a convergent parallel mixed-methods 
      design with quantitative surveys of known ICS and OCS AEs that were distributed 
      through the Allergy & Asthma Network database, social channels, and the Asthma UK 
      newsletter. Participants rated the AEs that were (1) most burdensome and (2) most 
      desired to be eliminated. Qualitative interviews and focus groups were performed 
      to better understand patient views on barriers reported in the quantitative data, 
      and to identify patient-important barriers that were not a part of the 
      quantitative survey. RESULTS: The 3 most burdensome AEs for OCS were bone mineral 
      density, infectious complications, and weight gain, whereas weight gain was the 
      most desired to be eliminated. The 3 most burdensome AEs for ICS were pneumonia, 
      hoarse voice, and oral thrush, with concordant results for the most desired to be 
      eliminated. In the focus groups, OCS AEs were concordant with quantitative 
      findings. Focus groups identified unmeasured psychosocial effects, such as 
      embarrassment. CONCLUSION: The most burdensome AEs may not be those that would 
      cause patients to stop therapy. Furthermore, qualitative focus groups suggest a 
      psychosocial burden associated with ICS, which needs further investigation.
CI  - Copyright (c) 2023 American College of Allergy, Asthma & Immunology. Published by 
      Elsevier Inc. All rights reserved.
FAU - Persaud, Purnadeo N
AU  - Persaud PN
AD  - Respiratory Institute, Cleveland Clinic, Cleveland, Ohio.
FAU - Tran, Annie P
AU  - Tran AP
AD  - International Consulting Associates, Inc, Arlington, Virginia.
FAU - Messner, Donna
AU  - Messner D
AD  - Center for Medical Technology Policy, Baltimore, Maryland.
FAU - Thornton, J Daryl
AU  - Thornton JD
AD  - The MetroHealth System, Cleveland, Ohio.
FAU - Williams, Dennis
AU  - Williams D
AD  - Allergy and Asthma Network, Vienna, Virginia; The University of North Carolina at 
      Chapel Hill Eshelman School of Pharmacy, Chapel Hill, North Carolina.
FAU - Harper, Logan J
AU  - Harper LJ
AD  - Respiratory Institute, Cleveland Clinic, Cleveland, Ohio.
FAU - Tejwani, Vickram
AU  - Tejwani V
AD  - Respiratory Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address: 
      Tejwanv@ccf.org.
LA  - eng
GR  - P60 MD002265/MD/NIMHD NIH HHS/United States
GR  - U54 MD002265/MD/NIMHD NIH HHS/United States
GR  - UL1 TR002548/TR/NCATS NIH HHS/United States
GR  - UM1 TR004528/TR/NCATS NIH HHS/United States
PT  - Journal Article
DEP - 20230827
PL  - United States
TA  - Ann Allergy Asthma Immunol
JT  - Annals of allergy, asthma & immunology : official publication of the American 
      College of Allergy, Asthma, & Immunology
JID - 9503580
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Adrenal Cortex Hormones)
SB  - IM
MH  - Humans
MH  - Quality of Life
MH  - *Anti-Asthmatic Agents/adverse effects
MH  - Administration, Inhalation
MH  - *Asthma/drug therapy/chemically induced
MH  - Adrenal Cortex Hormones/adverse effects
MH  - *Drug-Related Side Effects and Adverse Reactions
MH  - Weight Gain
MH  - Perception
PMC - PMC10843134
MID - NIHMS1936762
COIS- Disclosures The authors have no conflicts of interest to report.
EDAT- 2023/08/30 00:41
MHDA- 2023/12/05 12:42
PMCR- 2024/02/05
CRDT- 2023/08/29 19:14
PHST- 2023/01/17 00:00 [received]
PHST- 2023/07/19 00:00 [revised]
PHST- 2023/08/22 00:00 [accepted]
PHST- 2023/12/05 12:42 [medline]
PHST- 2023/08/30 00:41 [pubmed]
PHST- 2023/08/29 19:14 [entrez]
PHST- 2024/02/05 00:00 [pmc-release]
AID - S1081-1206(23)00636-1 [pii]
AID - 10.1016/j.anai.2023.08.595 [doi]
PST - ppublish
SO  - Ann Allergy Asthma Immunol. 2023 Dec;131(6):745-751.e11. doi: 
      10.1016/j.anai.2023.08.595. Epub 2023 Aug 27.